Cell Therapy News/Articles, page-16815

@whytee Nobody is doubting its an issue, that wasnt the point.

have you read what you have copy and pasted?

We will seek to extend our option to draw the additional $30.0 million tranche beyond September 30, 2023,

One clue there. If they are cooperative with the lender they can hash it out and negotiate new terms, term extension etc. Interest only til 2026 as well currently. They have also flagged their strategy for funding going forward outside of debt including, yes, capital markets.

but all that aside, here you are being super concerned as a non holder. Righty o.